



## **Akouos to Present at Cowen 42nd Annual Health Care Conference**

March 1, 2022

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. ("Akouos") (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will participate in a panel discussion titled *Auditory and Ophthalmology* at the Cowen 42<sup>nd</sup> Annual Health Care Conference on Monday, March 7 at 2:10 p.m. EST.

A live webcast of the event will be accessible through the investors section of [www.akouos.com](http://www.akouos.com). To access the webcast, please go to the Akouos website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. Archived replays will be available on the Akouos website for 30 days following the event.

### **About Akouos**

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.

### **Contacts**

#### Media:

Katie Engleman, 1AB  
katie@1abmedia.com

#### Investors:

Courtney Turiano, Stern Investor Relations  
Courtney.Turiano@sternir.com